Navigation Links
EntreMed's Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
Date:4/14/2008

New Drugs on the Horizon Session Highlights New Small Molecule Drug

Candidates

ROCKVILLE, Md., April 14 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of preclinical and mechanism of action data for its selective kinase inhibitor, ENMD-2076. On Sunday, April 13, 2008, Mark R. Bray, Ph.D., Vice President, Research, gave an oral presentation during the "New Drugs on the Horizon 2" symposium at the American Association for Cancer Research (AACR) Annual Meeting being held this week in San Diego, California.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

During the presentation, Dr. Bray highlighted ENMD-2076's unique combination of antiangiogenic, cell cycle, and antiproliferative activities. In preclinical studies, ENMD-2076 demonstrated potent activity against Aurora A and tyrosine kinases linked to promoting cancer and inflammatory diseases. ENMD-2076 acts through multiple pathways resulting in antiproliferative activity and the inhibition of angiogenesis. ENMD-2076 has demonstrated substantial, dose-dependent efficacy as a single agent in multiple xenograft models, including tumor regression in breast, colon, and leukemia models. ENMD-2076 is an orally active, multi-kinase inhibitor that has shown an acceptable toxicity profile in multiple preclinical studies without cardiovascular effects.

Dr. Bray commented on the presentation, "We are fortunate to have been selected to showcase the potent activity of ENMD-2076 during t
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
2. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
3. New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties
4. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
5. Study Shows Coronado Biosciences Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models
6. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
7. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
8. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
9. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
10. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
11. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Research and Markets has ... Industry Report 2014" report to their offering. ... 2014 is a professional and in-depth study on ... The report provides a basic overview ... industry chain structure. The N-acetylcysteine market analysis is ...
(Date:9/18/2014)... 2014 Research and Markets has ... (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends ... The global companion diagnostics market is ... 2014 to 2019. Factors such as rising need for ... diagnostics by the pharmaceutical industry, support from regulatory authorities, ...
(Date:9/18/2014)... ST. LOUIS , Sept. 18, 2014  U.S. ... portfolio by signing an exclusive license for technology developed ... to control gene expression in plants, including for applications ... species. The technology was developed under ... science officer at Kultevat and former president of the ...
(Date:9/18/2014)... 2014  Neogen Corporation (Nasdaq: NEOG ) ... agreement with Merck Animal Health to market Neogen,s Igenity ... Igenity Dairy Heifer Program consists of genomic tests that ... potential of replacement dairy heifers. The genomic tests can ... is an excellent tool in the decision-making process for ...
Breaking Biology Technology:Global N-acetylcysteine Industry Report 2014 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3Kultevat obtains license of gene switch technology 2Merck Animal Health to market Neogen's dairy genomic program 2
... LABS, Inc., the recognized leader in microbiology, infectious ... the transplant and biomedical sciences communities, today announced ... President of Strategic Development following two years with ... LABS, Inc. client base significantly. In ...
... announced the sale of its leading Sustenex® ... dietary supplements to Schiff Nutrition International, Inc. ... royalties on Schiff products containing GanedenBC30 ™.  The ... probiotic technology, GanedenBC30™, in the over-the-counter (OTC) and dietary ...
... 2011 To aid the fight of the deadly ... and their collaborators at the University Medical Centre Hamburg-Eppendorf ... upon the sequencing data previously released and submitted to ... the first genomes assembled using the latest ion semiconductor ...
Cached Biology Technology:LABS, Inc. Promotes Chad Ronholdt to VP of Strategic Development 2Ganeden Biotech Completes $40 Million Sale of Sustenex® and Digestive Advantage® Probiotic Brands 2Ganeden Biotech Completes $40 Million Sale of Sustenex® and Digestive Advantage® Probiotic Brands 3Further Analysis on Improved Genome Assembly Indicates the Outbreak E. coli has Complex Genetics With Resistance to at Least Eight Antibiotics 2Further Analysis on Improved Genome Assembly Indicates the Outbreak E. coli has Complex Genetics With Resistance to at Least Eight Antibiotics 3
(Date:9/18/2014)... the fish world, are the ideal animal in which ... moved from the ocean into tens of thousands of ... changing their skeleton to adapt to the new environment. ... sticklebacks now have turned up one of the genes ... change in that gene,s regulation in a freshwater population ...
(Date:9/18/2014)... has found clownfish larvae can swim up to 400 kilometres ... to cope with environmental change. , Clownfish spend their entire ... as babies they must wander the open ocean, says study ... for Coral Reef Studies (Coral CoE) at James Cook University. ... but now we,ve been given a rare glimpse into how ...
(Date:9/17/2014)... to reproductive technologies, the justice and well-being of ... to identify key issues, articulate their values and ... most defensible ways forward. But what are the ... The Hastings Center and the Presidential Commission for ... to publish a series of essays to highlight ...
Breaking Biology News(10 mins):Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3Nemo's epic journey to find a new home 2Why bioethics literacy matters 2Why bioethics literacy matters 3
... that as some populations of an organism evolve a ... segment of the lifespan that contributes to "fitness" ?the ... the next generation. , Focusing on guppies, small fresh-water ... that guppies living in environments with a large number ...
... teeth and jawbones of two new species of tiny monkey-like ... from ancient sediments in the Egyptian desert, researchers have reported. ... common ancestor of living anthropoids -- including monkeys, apes and ... already begun branching into many species by that time. Also, ...
... Institute of Allergy and Infectious Diseases (NIAID), part ... how a promising drug candidate attacks the bacterium ... in Proceedings of the National Academy of Sciences, ... candidate, PA-824, which targets Mycobacterium tuberculosis (M. tb). ...
Cached Biology News:Fish evolve a longer lifespan by evolving a longer reproductive period, researchers find 2Ancient anthropoid origins discovered in Africa 2Ancient anthropoid origins discovered in Africa 3NIAID researchers show how promising TB drug works 2NIAID researchers show how promising TB drug works 3
HP 1 alpha Immunogen: Synthetic peptide between amino acids 1-100 of the human HP 1 alpha protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... subcloning of gene in baculoviral expression ... and plaque purification of ten clones, ... for one clone, protein expression and ... culture. Expected yield and timeline: 1-4 ...
... Custom Synthesis Service provides you ... to knockdown any gene. We ... base pairs with terminal dT ... other lengths of your choice. ...
EDG-1 Western blot control Source: Cell Lysate Application: Western Blotting Control...
Biology Products: